DEFB107A
Beta-defensin 107
Also known as: D107A_HUMAN, DEFB-7, DEFB107, DEFB107B, HsT21816
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q8IZN7
- Gene
- DEFB107A
- Ensembl
- ENSG00000186572
- Chromosome
- 8
- Canonical length
- 70 aa
- Protein class
- Predicted secreted proteins
- Secretome location
- Secreted in male reproductive system
OverviewNCBI Gene
Defensins form a family of antimicrobial and cytotoxic peptides made by neutrophils. Defensins are short, processed peptide molecules that are classified by structure into three groups: alpha-defensins, beta-defensins and theta-defensins. All beta-defensin genes are densely clustered in four to five syntenic chromosomal regions. Chromosome 8p23 contains at least two copies of the duplicated beta-defensin cluster. This duplication results in two identical copies of defensin, beta 107, DEFB107A and DEFB107B, in tail-to-tail orientation. This gene, DEFB107A, represents the more centromeric copy. [provided by RefSeq, Oct 2014]
Canonical amino-acid sequenceUniProt
70 residues, UniProt reviewed canonical sequence.
>Q8IZN7|DEFB107A
1 MPGAMKIFVF ILAALILLAQ IFQARTAIHR ALISKRMEGH CEAECLTFEV KIGGCRAELA
61 PFCCKNRKKHLocalizationUniProt · AlphaFold · HPA
Whether an antibody against DEFB107A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.46
- Highest tissue expression
- 132 nTPM
Expression across tissuesHPA
Tissue
- epididymis: 132 nTPM
- adipose tissue: 0 nTPM
- adrenal gland: 0 nTPM
- amygdala: 0 nTPM
- appendix: 0 nTPM
- basal ganglia: 0 nTPM
Single-cell type
- epididymal principal cells: 3.6 nCPM
- podocytes: 0.3 nCPM
- renal connecting tubule cells: 0.1 nCPM
- adipocytes: 0 nCPM
- adrenal cortex cells: 0 nCPM
- adrenal medulla cells: 0 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- amygdala: 0 nTPM
- basal ganglia: 0 nTPM
- cerebellum: 0 nTPM
- cerebral cortex: 0 nTPM
- choroid plexus: 0 nTPM
- hippocampal formation: 0 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.85
- gnomAD pLI
- 0.33
- gnomAD missense Z
- 0.76
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 1% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads DEFB107A as an antibody target. Whether an autoantibody or antibody against DEFB107A could matter depends on whether native DEFB107A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
DEFB107A is annotated as secreted, so native DEFB107A circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label DEFB107A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...